Skip to content

Prospective, Multicenter, Randomized Controlled, Non-Inferiority Clinical Trial Evaluating the Safety and Efficacy of Absorbable Soft Tissue Repair Membrane for the Repair of Superficial Oral Soft Tissue Defects

Prospective, Multicenter, Randomized Controlled, Non-Inferiority Clinical Trial Evaluating the Safety and Efficacy of Absorbable Soft Tissue Repair Membrane for the Repair of Superficial Oral Soft Tissue Defects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109565
Enrollment
Unknown
Registered
2025-09-22
Start date
2025-10-09
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral soft tissue defects

Interventions

Experimental group:Absorbable Soft Tissue Repair Membrane
Control Group:Oral Repair Membrane

Sponsors

West China Hospital of Stomatology, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 70 years inclusive, regardless of gender; 2. Patients with superficial oral soft tissue defects of various etiologies requiring wound coverage with a repair membrane; 3. Individuals who agree to participate in this clinical trial and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Use of oral membrane materials (e.g., for soft tissue augmentation, defect repair, etc.) at the target wound site within 6 months prior to surgery; 2. Presence of local infection at the defect site or systemic infection; 3. Single wound area 25 cm^2; 4. Poorly controlled diabetes (fasting blood glucose =8.8 mmol/L or 2-hour postprandial blood glucose >=11.1 mmol/L); 5. History of radiotherapy prior to surgery or chemotherapy within 6 months before surgery; 6. Hepatic or renal insufficiency (ALT, AST, or Scr >2 times the upper limit of normal); 7. Severe coagulation disorders (PT or APTT >2 times the upper limit of normal); 8. Hypoalbuminemia (serum albumin <30 g/L) or cachexia; 9. Diagnosis of autoimmune diseases; 10. Intolerance to surgery or contraindications for surgical procedures; 11. Allergy to collagen or materials of ovine (sheep) or bovine (cattle) origin; 12. History of alcohol abuse or substance misuse; 13. Pregnancy or lactation, or planning pregnancy during the study period; 14. Current participation in other interventional drug or device clinical trials without having reached the primary endpoint; 15. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.

Design outcomes

Primary

MeasureTime frame
The Grade A Healing Rate of the Target Wound at 1 Month Postoperatively;

Countries

China

Contacts

Public ContactLing Ye

West China Hospital of Stomatology, Sichuan University

yeling@scu.edu.cn+86 135 5015 5522

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026